Metastasis Free Survival
NUBEQA + ADT more than doubled median MFS vs ADT
In the phase 3 ARAMIS trial, NUBEQA + ADT
Median MFS in men with nmCRPC (primary endpoint)
Adapted from Fizazi K et al. 2019.
ARAMIS Study:
ARAMIS is a double-blind, randomised, placebo-controlled, multicentre phase 3 study in 1,509 nmCRPC patients with PSA doubling time of ≤ 10 months. Patients were randomised 2:1 to receive NUBEQA + ADT 600 mg bd (n=955) or placebo + ADT (n=554). The primary endpoint was metastasis-free survival. The planned primary analysis was performed after 437 primary end-point events had occurred.
Abbreviations:
PP-NUB-IE-0265-1 | December 2025